Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

She had been diagnosed as having metastatic pulmonary neuroendocrine tumor. The patient's medical ... plasma chromogranin A levels to 463 µg/l (Table 1 and Figure 2), imaging procedures ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...